Targets › NOTCH4
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2027.
Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. (UniProt, Q99466)
Open in Phaseline: the race on NOTCH4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Michael J. Dennis, MD | CB-103 Pan-NOTCH pathway inhibitor | NOTCH1, NOTCH2, NOTCH3, NOTCH4 | Phase 1 | Adenoid Cystic Carcinoma | Jun 2027 |
Adenoid Cystic Carcinoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.